Chugai and Biofourmis Collaborating to Develop Digital Solution For Objective Assessment of Pain

Chugai Biofourmis partnership
Biofourmis’ Biovitals platform collects and interprets vast amounts of population metadata and compares it to real-time patient physiological signals to provide a clearer picture of chronic patients and their disease trajectory (Image: Biofourmis)
Chugai Pharmaceutical, one of Japan’s leading research-based pharmaceutical companies and Biofourmis, a Boston-based digital therapeutics company, announced that they have partnered to develop a digital solution for the objective assessment of pain associated with endometriosis. Read more Wearables In Combination With Digital Technology Offers Huge Opportunities For Non-Invasive Pain Management Endometriosis is the repeated proliferation […]